Table 1.
Characteristics of hip/femur fracture cases and controls in the GPRD and PHARMO RLS
| Characteristic | GPRD | PHARMO RLS | ||
|---|---|---|---|---|
| Cases (n = 22,247) | Controls (n = 22,247) | Cases (n = 6,763) | Controls (n = 26,341) | |
| Gender | ||||
| Women | 75.8% | 75.8% | 72.9% | 72.7% |
| Age (years) | ||||
| <65 | 13.9% | 13.9% | 15.8% | 16.2% |
| 65–79 | 30.8% | 32.2% | 36.6% | 37.3% |
| ≥80 | 55.2% | 53.9% | 47.6% | 46.5% |
| Smokinga | 22.1% | 20.6% | No data available | |
| BMIb | ||||
| 20–25 | 46.6% | 42.4% | ||
| <20 | 18.0% | 9.7% | No data available | |
| >25 | 35.4% | 47.9% | ||
| Antidepressants | 13.0% | 7.2% | 9.5% | 5.1% |
| Oral glucocorticoids | 7.2% | 4.4% | 5.4% | 3.5% |
| Thiazides | 11.9% | 12.9% | 12.1% | 11.4% |
| Nitrates | 6.9% | 7.4% | 9.4% | 9.1% |
| Hormone replacement | 0.6% | 1.2% | 1.1% | 1.3% |
a No data on smoking status for 45% of GPRD study population
b No data on BMI for 58.5% of GPRD study population